Report Highlights

UK Dry Ice Market: Market Overview

The UK dry ice market is structurally distinct from broader European peers due to its outsized pharmaceutical demand base, which accounts for an estimated 41% of total consumption — nearly double the EU average of 22%. This skew reflects the UK's position as home to major biologics manufacturers including AstraZeneca, GSK, and a dense network of contract research organisations concentrated in the Oxford-Cambridge Arc and the Scottish Life Sciences Corridor. Unlike markets in Germany or France, the UK dry ice sector operates without a legacy industrial gas nationalisation framework, meaning pricing is more market-driven but also more fragmented.

Market size reached USD 142.6 million in 2024 and is forecast to grow at a 6.2% CAGR through 2032, reaching USD 231.4 million. The UK market is served primarily by vertically integrated industrial gas majors — BOC (Linde), Air Products, and Air Liquide — that manufacture dry ice as a by-product of CO2 captured from industrial and fermentation processes. The food processing and hospitality segments, while meaningful, are secondary demand centres. Market concentration is high: the top three producers control an estimated 72% of installed production capacity, creating significant structural barriers for new standalone dry ice manufacturers.

Growth Drivers in the UK Dry Ice Market

The single most important demand driver is the UK's post-Brexit pharmaceutical regulatory realignment under the Medicines and Healthcare products Regulatory Agency (MHRA), which has accelerated domestic biologics manufacturing investment. The MHRA's Innovative Licensing and Access Pathway (ILAP), introduced in 2021 and expanded in 2023, has fast-tracked approval of temperature-sensitive biologics requiring dry ice storage at -78.5°C. The NHS Long Term Plan's commitment to personalised medicine and cell and gene therapies — with a GBP 200 million investment envelope — directly translates into sustained dry ice demand growth through 2032 as these therapies cannot be distributed via conventional cold chain infrastructure.

Secondary drivers include the rapid expansion of UK meal kit and premium e-grocery delivery, where operators such as Gousto, HelloFresh UK, and Ocado use dry ice as a passive cooling medium to extend ambient delivery windows and reduce gel pack logistics costs. Additionally, the UK's net-zero industrial strategy has paradoxically supported dry ice demand: carbon capture projects at facilities including the Drax biomass plant in Yorkshire and the HyNet cluster in the North West produce high-purity CO2 streams, improving domestic feedstock availability for dry ice production and stabilising production economics for manufacturers investing in capacity expansion.

Market Restraints and Entry Barriers

The dominant entry barrier in the UK dry ice market is feedstock dependency on industrial CO2 supply, which is tightly controlled by the same vertically integrated majors that dominate dry ice production. The 2021–2022 CO2 shortage — triggered by planned maintenance shutdowns at CF Fertilisers' Billingham and Ince plants, which together supplied approximately 60% of UK food-grade CO2 — exposed the systemic vulnerability of independent dry ice producers to upstream supply disruptions. New entrants without guaranteed CO2 offtake agreements face significant feedstock security risk, and negotiating such agreements with BOC or Air Products from a position of limited volume is structurally difficult.

Regulatory compliance adds a further layer of complexity. Dry ice used in pharmaceutical distribution must comply with GDP (Good Distribution Practice) guidelines enforced under the Human Medicines Regulations 2012 (as amended post-Brexit). Facilities handling dry ice for pharmaceutical purposes require MHRA Wholesale Dealer's Authorisation, which involves inspection timelines of six to twelve months. For food-contact applications, compliance with UK Food Safety Act 1990 and EC Regulation 1935/2004 (retained in UK law) adds further documentation requirements. Combined, these compliance burdens create meaningful cost and time disadvantages for market entrants relative to established participants operating under long-standing regulatory approvals.

Market Opportunities in the UK Dry Ice Market

The most immediately addressable opportunity lies in pharmaceutical last-mile dry ice logistics, specifically the last-metre delivery of advanced therapy medicinal products (ATMPs) to NHS hospital pharmacies and clinical trial sites. The UK currently has over 5,000 active clinical trials, and approximately 18% involve temperature-sensitive biologics requiring dry ice transport according to MHRA trial registry data. No single logistics provider currently holds dominant share in this specialised sub-segment, meaning a focused cold chain logistics operator with MHRA GDP certification and validated dry ice packaging solutions — such as insulated shippers compliant with ISTA 7E or IATA P650 — faces an addressable sub-market estimated at GBP 28–34 million annually.

A second near-term opportunity exists in industrial dry ice blasting services, where the UK manufacturing sector — particularly aerospace components cleaning at facilities in Bristol and Derby, and automotive tooling maintenance in the West Midlands — is transitioning away from solvent-based cleaning methods under REACH (UK) regulation restrictions on hazardous substances. The UK dry ice blasting services segment is estimated at GBP 18 million in 2024 and is growing at approximately 8.4% annually. Entering via equipment leasing and service contracts rather than dry ice production eliminates feedstock risk while capturing value-added margin in an underserved industrial cleaning application.

Market at a Glance

Leading Market Participants

• BOC (Linde plc, UK operations)
• Air Products plc
• Air Liquide UK Ltd
• Messer UK Ltd
• Dry Ice UK Ltd
• Carbon Dioxide Supply Ltd (CDSL)
• ICE DRY UK
• Cold Chain Technologies (UK distribution)
• Polar Tech Industries (UK)
• Praxair Distribution Ltd

Regulatory and Policy Environment

The UK dry ice market operates under a multi-agency regulatory framework that has evolved significantly since Brexit. The MHRA enforces Good Distribution Practice for pharmaceutical applications under the Human Medicines Regulations 2012 (SI 2012/1916), and its 2023 update to GDP guidelines explicitly references dry ice as a critical packaging component for ATMPs and mRNA products, requiring temperature excursion documentation and qualified person sign-off for each shipment. The Health and Safety Executive (HSE) governs occupational CO2 and asphyxiation risk under COSHH Regulations 2002, mandating risk assessments for any facility storing more than 25 kg of dry ice. Transport falls under the Carriage of Dangerous Goods Regulations 2009 (CDG 2009), classifying dry ice as UN1845, Class 9, with ADR-compliant labelling and quantity limits per consignment.

On the supply side, the UK Government's Food Security and Supply Taskforce — established following the 2021 CO2 crisis — has maintained an Emergency CO2 Agreement with CF Fertilisers, providing GBP 20 million in standby funding to prevent repeat supply shocks. HMRC zero-rates dry ice under VAT when sold for food preservation purposes, but standard 20% VAT applies in industrial and pharmaceutical applications, creating a material cost differential that affects pricing strategies across segments. The UK's Carbon Border Adjustment Mechanism (CBAM) consultation, ongoing through 2025, will determine whether imported CO2 — currently supplying approximately 12% of UK dry ice feedstock from continental Europe — faces additional carbon cost levies from 2027, a regulatory risk that forward-thinking market participants are already hedging through domestic sourcing agreements.

Long-Term Outlook for the UK Dry Ice Market

By 2032, the UK dry ice market will be substantially reshaped by three structural forces: the maturation of the UK cell and gene therapy manufacturing cluster, the full deployment of NHS Pharmacy First logistics infrastructure, and the consolidation of CO2 capture from industrial decarbonisation projects into commercial dry ice feedstock supply chains. The Oxford-Cambridge Arc and the Scottish Life Sciences Corridor will account for a disproportionate share of pharmaceutical dry ice demand, and logistics operators that have established GDP-certified distribution hubs in these geographies by 2027 will hold durable competitive positions that new entrants will find prohibitively expensive to replicate.

The competitive landscape will consolidate further, with BOC and Air Products likely to extend their market share through acquisition of smaller regional distributors unable to absorb compliance cost inflation. However, a viable third tier of specialist logistics and blasting services companies will persist, capturing niche margin pools in clinical trial distribution and industrial cleaning. The introduction of reusable dry ice packaging systems — driven by the UK's Environment Act 2021 Extended Producer Responsibility framework — will shift cost structures toward service models, favouring operators with established customer relationships over volume-based commodity dry ice suppliers. The market trajectory to USD 231.4 million by 2032 is underpinned by inelastic pharmaceutical demand that insulates the UK market from broader economic cycles.